Why Pulmonx Corporation’s (LUNG) Stock Is Down 9.64%
As of Friday, October 30, Pulmonx Corporation’s LUNG share price has dipped by 9.64%, which has investors questioning if this is right time to buy.Michael Rose
Stock Evaluator: Pulmonx Corporation (LUNG)
Pulmonx Corporation LUNG
$3.01
-0.16
-5.06%
October 30, 2026 4:00:00 PM
EST
Volume: 2,398,753
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Commentary & Analysis
Why Pulmonx Corporation’s (LUNG) Stock Is Up 11.31%
As of Thursday, October 29, Pulmonx Corporation’s LUNG share price has surged by 11.31%, which has investors questioning if this is right time to sell.Michael Rose
Why Pulmonx Corporation’s (LUNG) Stock Is Up 27.02%
As of Wednesday, October 28, Pulmonx Corporation’s LUNG share price has surged by 27.02%, which has investors questioning if this is right time to sell.Michael Rose
What You Need to Know About Pulmonx Corporation's Q4 Earnings
Pulmonx Corporation's fiscal Q4 earnings report was released on Tuesday, October 27. Let's dive in to see if (LUNG) missed or beat analyst's expectations.Tudor Pop
Why Pulmonx Corporation’s (LUNG) Stock Is Down 6.04%
As of Monday, September 21, Pulmonx Corporation’s LUNG share price has dipped by 6.04%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | LUNG | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $129.3 | $383.9 | 24% |
|
| Shares Out (Mil) | 42.5 | 40.6 | 44% |
|
| Institutional Ownership | 90.2% | 83.3% | 58% |
|
| Float (Mil) | 37.6 | 35.1 | 40% |
|
| Beta | na | 0.90 | na |
|
| Avg Daily Volume (000s) | 1,746 | 323 | 79% |
|
| Price Change (52-week) |
56.8% | 62.8% | 88% |
|
| Growth | LUNG | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 22.6% | 11.8% | 84% |
|
| Net Income (5yr) | (10.9%) | (5.6%) | 28% |
|
| EPS (5yr) | 16.0% | 10.6% | 60 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (14.9%) | (15.6%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 4 | 4 | |
| Current EPS | ($0.227) | ($0.978) | ($0.883) | |
| Month Ago EPS | ($0.218) | ($1.044) | ($0.942) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.218) | ($1.044) | ($0.942) | |
| Year/Year Chg | (4.2%) | (26.3%) | (47.2%) | |
| Financials | LUNG | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $87 | $141 | 25% |
|
| Net Income (TTM) (Mil) | ($48) | ($10) | 16% |
|
| EPS (TTM) | ($1.154) | ($0.400) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($31) | ($2) | 12% |
|
| Net Cash Flow (TTM) (Mil) | ($20) | $1 | 27% |
|
| Long-Term Debt (Q1) (Mil) | $55 | $25 | 40% |
|
| Enterprise Value (Q1) (Mil) | $109 | $381 | 22% |
|
| Valuation | LUNG | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.31 | 2.46 | 71% |
|
| P/E | na | 28.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.4 | na |
|
| Ratios | LUNG | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 77.4% | 59.3% | 87% |
|
| Net Margin | (47.9%) | (6.9%) | 12% |
|
| ROA | (36.7%) | (12.1%) | 15% |
|
| ROE | (88.9%) | (10.3%) | 10% |
|
| Liabilities to Assets | 65.8% | 47.2% | 61% |
|
| F-Score | 3 | 4 | 18% |
|
Pulmonx Corporation did not pass any screens on 10/30/2026.
